SBIO vs. BFOR
SBIO (ALPS Medical Breakthroughs ETF) and BFOR (ALPS Barron's 400 ETF) are both exchange-traded funds - SBIO is a Health & Biotech Equities fund tracking the S-Network Medical Breakthroughs Index, while BFOR is a Mid Cap Blend Equities fund tracking the Barron's 400 Index. Both are passively managed. Over the past 10 years, SBIO returned 8.03%/yr vs 12.39%/yr for BFOR. A 0.59 correlation means they provide meaningful diversification when combined. SBIO charges 0.50%/yr vs 0.65%/yr for BFOR.
Performance
SBIO vs. BFOR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SBIO achieves a 1.95% return, which is significantly lower than BFOR's 11.03% return. Over the past 10 years, SBIO has underperformed BFOR with an annualized return of 8.03%, while BFOR has yielded a comparatively higher 12.39% annualized return.
SBIO
- 1D
- 2.35%
- 1M
- -5.55%
- YTD
- 1.95%
- 6M
- 4.13%
- 1Y
- 68.86%
- 3Y*
- 18.38%
- 5Y*
- 3.16%
- 10Y*
- 8.03%
BFOR
- 1D
- 1.03%
- 1M
- 1.90%
- YTD
- 11.03%
- 6M
- 11.30%
- 1Y
- 23.59%
- 3Y*
- 20.15%
- 5Y*
- 10.21%
- 10Y*
- 12.39%
SBIO vs. BFOR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SBIO ALPS Medical Breakthroughs ETF | 1.95% | 55.07% | 3.81% | 8.68% | -28.08% | -17.55% | 21.17% | 50.30% | -11.81% | 45.67% |
BFOR ALPS Barron's 400 ETF | 11.03% | 13.85% | 17.81% | 18.19% | -15.92% | 30.71% | 17.60% | 21.30% | -13.86% | 19.37% |
Correlation
The correlation between SBIO and BFOR is 0.49, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.49 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.57 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.57 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.59 |
Correlation (All Time) Calculated using the full available price history since Jan 2, 2015 | 0.59 |
The correlation between SBIO and BFOR has been stable across timeframes, ranging from 0.49 to 0.59 - a consistent structural relationship.
SBIO vs. BFOR - Sectors Allocation Comparison
Sectors
SBIO
BFOR
Healthcare
Basic Materials
-
Communication Services
-
Consumer Cyclical
-
Consumer Defensive
-
Energy
-
Industrials
-
Real Estate
-
-
Technology
-
Utilities
-
Financial Services
Healthcare
SBIO
BFOR
Basic Materials
SBIO
-
BFOR
Communication Services
SBIO
-
BFOR
Consumer Cyclical
SBIO
-
BFOR
Consumer Defensive
SBIO
-
BFOR
Energy
SBIO
-
BFOR
Industrials
SBIO
-
BFOR
Real Estate
SBIO
-
BFOR
-
Technology
SBIO
-
BFOR
Utilities
SBIO
-
BFOR
Financial Services
SBIO
BFOR
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SBIO vs. BFOR — Risk / Return Rank
SBIO
BFOR
SBIO vs. BFOR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and ALPS Barron's 400 ETF (BFOR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SBIO | BFOR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.75 | ||
| Sortino ratioReturn per unit of downside risk | +0.85 | ||
| Omega ratioGain probability vs. loss probability | 1.38 | 1.28 | +0.09 |
| Calmar ratioReturn relative to maximum drawdown | 5.47 | 2.64 | +2.83 |
| Martin ratioReturn relative to average drawdown | 16.23 | 9.65 | +6.58 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SBIO | BFOR | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.35 | 1.60 | +0.75 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.09 | 0.53 | -0.43 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.24 | 0.61 | -0.37 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.22 | 0.59 | -0.37 |
Drawdowns
SBIO vs. BFOR - Drawdown Comparison
The maximum SBIO drawdown since its inception was -63.06%, which is greater than BFOR's maximum drawdown of -41.27%. Use the drawdown chart below to compare losses from any high point for SBIO and BFOR.
Loading charts...
Drawdown Indicators
| SBIO | BFOR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.06% | -41.27% | -21.79% |
Max Drawdown (1Y)Largest decline over 1 year | -12.66% | -8.98% | -3.68% |
Max Drawdown (3Y)Largest decline over 3 years | -42.44% | -21.91% | -20.53% |
Max Drawdown (5Y)Largest decline over 5 years | -53.10% | -25.93% | -27.17% |
Max Drawdown (10Y)Largest decline over 10 years | -63.06% | -41.27% | -21.79% |
Current DrawdownCurrent decline from peak | -14.84% | 0.00% | -14.84% |
Average DrawdownAverage peak-to-trough decline | -28.44% | -6.42% | -22.02% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.26% | 2.45% | +1.81% |
Volatility
SBIO vs. BFOR - Volatility Comparison
ALPS Medical Breakthroughs ETF (SBIO) has a higher volatility of 9.85% compared to ALPS Barron's 400 ETF (BFOR) at 3.40%. This indicates that SBIO's price experiences larger fluctuations and is considered to be riskier than BFOR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SBIO | BFOR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.85% | 3.40% | +6.45% |
Volatility (6M)Calculated over the trailing 6-month period | 22.76% | 10.68% | +12.08% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.40% | 14.81% | +14.59% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.57% | 19.42% | +14.15% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 33.18% | 20.41% | +12.77% |
SBIO vs. BFOR - Expense Ratio Comparison
SBIO has a 0.50% expense ratio, which is lower than BFOR's 0.65% expense ratio.
Dividends
SBIO vs. BFOR - Dividend Comparison
SBIO has not paid dividends to shareholders, while BFOR's dividend yield for the trailing twelve months is around 0.54%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BFOR ALPS Barron's 400 ETF | 0.54% | 0.60% | 0.69% | 1.26% | 1.68% | 0.92% | 0.98% | 0.69% | 0.94% | 0.60% | 0.78% | 0.86% |
SBIO ALPS Medical Breakthroughs ETF | 0.00% | 0.00% | 3.55% | 0.22% | 0.00% | 0.00% | 0.00% | 0.04% | 2.79% | 1.77% | 0.00% | 0.00% |
Frequently Asked Questions
SBIO and BFOR have a correlation of 0.49, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SBIO has higher volatility (9.85%) compared to BFOR (3.40%). In terms of maximum drawdown, SBIO dropped -63.06% vs BFOR's -41.27%.
On 10-year performance, BFOR leads with 12.39% vs 8.03% for SBIO. On fees, SBIO is cheaper at 0.50% per year. On volatility, BFOR has been the lower-risk option at 3.40%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, BFOR has performed better with a 12.39% return vs 8.03%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
SBIO is cheaper with a 0.50% expense ratio, compared with 0.65% for BFOR.
BFOR has the higher dividend yield at 0.54%, compared with 0.00% for SBIO.
SBIO is categorized as Health & Biotech Equities, while BFOR is Mid Cap Blend Equities. SBIO tracks S-Network Medical Breakthroughs Index, while BFOR tracks Barron's 400 Index. Their fees differ too: 0.50% for SBIO and 0.65% for BFOR.
SBIO currently has the higher Sharpe Ratio (2.35 vs 1.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SBIO and BFOR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer